Status:
COMPLETED
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Heart Failure With Preserved Ejection Fraction
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ...
Detailed Description
This was a multicenter, randomized, double-blind, parallel group, active-controlled, study to evaluate the efficacy and safety of sacubitril/valsartan compared to valsartan, on morbidity and mortality...
Eligibility Criteria
Inclusion
- Left ventricular ejection fraction (LVEF) ≥45% by echo during screening epoch or within 6 months prior to study entry.
- Symptom(s) of heart failure (HF) and requiring treatment with diuretic(s) for HF at least 30 days prior to study entry.
- Current symptom(s) of HF (NYHA class II-IV)
- Structural heart disease (left atrial enlargement or left ventricular hypertrophy) documented by echocardiogram.
- Elevated NT-proBNP
Exclusion
- Any prior measurement of LVEF \< 40%.
- Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within 3 months , or urgent percutaneous coronary intervention within 3 months or and elective PCI within 30 days prior to entry.
- Any clinical event within the 6 months prior to entry could have reduced the LVEF (e.g., MI, CABG), unless an echo measurement performed after the event confirms a LVEF ≥45%.
- Current acute decompensated HF requiring therapy.
- Patients who require treatment with 2 or more of the following: an angiotensin converting enzyme inhibitor (ACEI), an angiotensin receptor blocker (ARB) or a renin inhibitor.
- Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) \<10 g/dl, or body mass index (BMI) \> 40 kg/m2.
- Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP \>150 mmHg and \<180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs, or SBP \< 110 mmHg at entry.
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
July 18 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 7 2019
Estimated Enrollment :
4822 Patients enrolled
Trial Details
Trial ID
NCT01920711
Start Date
July 18 2014
End Date
June 7 2019
Last Update
September 29 2020
Active Locations (715)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Huntsville, Alabama, United States, 35801
2
Novartis Investigative Site
Mobile, Alabama, United States, 36608
3
Novartis Investigative Site
Muscle Shoals, Alabama, United States, 35662
4
Novartis Investigative Site
Little Rock, Arkansas, United States, 72204